64 results about "Cross immunity" patented technology

The present invention is pneumococus polysaccharide protein coupling vaccine comprising covalently connected pneumococus capsule polysaccharide and recombinant pneumolysin without hemolytic activity modification and its preparation process. The vaccine has pneumolysin without hemolytic activity as protein carrier, no need of eliminating hemolysis toxicity of pneumolysin with formalin and ensured safety, and may be used for infant below 2 yeas old to prevent tympanitis. Owing to the pneumolysin as the self protein, the vaccine has no probable immune interference reaction and strengthened immune protecting effect. The vaccine has cross immunizing protection effect on various kinds of serum type pneumococus and raised immune memory response to pneumococus infection.

The invention discloses an electrochemical immunodetection method for detecting estrols comprising three artificial synthesized compounds possessing estrogen-like effects, and the three compounds are diethylstilbestrol, hexestrol and bisphenol A. The detection method comprises: preparing an electrochemical sensor which has deposited nano-gold and is modified by a graphene / estrol / chitosan compound, then taking K3[Fe(CN)6] as a probe, based on the cross immunity reaction of diethylstibestrol antibody to diethylstilbestrol, hexestrol and bisphenol A, achieving the detection on the three estrols. According to the method provided by the invention, the detection limit of diethylstibestrol is 0.1 ng / mL, linearity range is 1-2500 ng / mL; the detection limit of hexestrol is 0.3 ng / mL, linearity range is 1-3000 ng / mL; and the detection limit of bisphenol A is 0.2 ng / mL, linearity range is 1-3000 ng / mL.

A bacterin for fish farming is used to treat vibriosis with reduced toxicity. The vaccine is mainly formed by no marker gene deletion strains with toxicity reduced. It is effective for cross immunization of Rongzao vibrios. The vaccine made from it can effectively be used to prevent testing fishes from diseases caused by vibriosis.

The invention discloses a chimeric strain of a porcine reproductive and respiratory syndrome virus and application thereof. Based on a full-length infectious cDNA clone of an attenuated strain of highly pathogenic PRRSV TJM-F92 vaccine and a NADC30-like subtype strain FJ1402, a reverse genetic technology is utilized to construct the chimeric strain of the porcine reproductive and respiratory syndrome virus. It is verified by tests that the chimeric strain has a lower virus growth speed and virus titer on Marc-145 cells than the original strain TJM-F92, and the virulence is low. The chimeric strain has a good immunoprotective effect on HP-PRRSV strain BB0907 and NADC30-like strain FJ1402 and can provide effective cross-immunization protection against infections of highly pathogenic strainsand NADC30-like strains, which lays an important foundation for the development of new broad-spectrum vaccines against this disease.

The invention discloses anti-tumor ubiquitinated protein which is mainly extracted from the following steps: (1) culture of tumor cells: resuscitating cryopreserved tumor cells and culturing the tumor cells according to a conventional culture method; (2) treatment of the tumor cells; and (3) extraction of the ubiquitinated protein. The invention further discloses an extraction method of the anti-tumor ubiquitinated protein as well as application of the anti-tumor ubiquitinated protein in preparing tumor therapeutic vaccines. Compared to the prior art, the protein disclosed by the invention can be used for greatly improving the effect of cross-immuno reaction and improving the inhibitory effect on different types of tumors to a great extent; in addition, the problem that ubiquitinated short-lived protein is fast to degrade is further overcome, and a lot of ubiquitinated protein can be quickly obtained. Finally, the asymmetry between the short-lived protein and the long-lived protein is overcome, the target spots for inducing specific effector cells are increased, and the defect that the anti-tumor vaccines are poor in anti-tumor effect based on the long-lived protein is remedied.

The invention discloses an application of a dienestrol antibody in an immune electrochemical detection method of simultaneous detection of three female hormone analogous compounds, namely, diethylstilbestrol, dienestrol and hexestrol. The detection method includes following steps: (1) preparing an electrochemical sensor deposited by nano gold and modified by a graphene / strol / chitosan composition; (2) with K3[Fe(CN)6] as a probe, performing the simultaneous detection of the three strol on the basis of a cross immunoreaction of the dienestrol antibody to the three strol. In the method, a detection limit is 0.2 ng / mL and a linearity range is 1-4000 ng / mL of the diethylstilbestrol; the detection limit is 0.05 ng / mL and the linearity range is 10-4000 ng / mL of the dienestrol; and the detection limit is 0.5 ng / mL and the linearity range is 100-4000 ng / mL of the hexestrol.

The invention relates to biological immunity and a vaccine, and in particular discloses a coccidiosis vaccine component having a cross immunological protection capacity and a vaccine containing the coccidiosis vaccine component. The coccidiosis vaccine component is a transgenic coccidiosis strain capable of expressing heterogeneous coccidiosis immunity dominant antigens. The transgenic coccidiosis strain, which simultaneously has immunogenicities of a parental coccidiosis strain and a heterogeneous coccidiosis strain, can enhance the cross immunological protection capacity of the coccidiosis vaccine component when the transgenic coccidiosis strain serves as the coccidiosis vaccine component. Based upon experimental studies, it discovers that the cross immunological protection capacity, which is provided by the novel vaccine component, is positively correlated to the quantity of the expressed heterogeneous dominant antigens; therefore, preferably, a plurality of immunity dominant antigens are expressed. According to the coccidiosis vaccine component and a construction strategy thereof provided by the invention, the immunological protection capacity can be offered for various insect infections; and the cross immunological protection capacity is universal.

The invention discloses a genetic engineering subunit mixed vaccine as well as a preparation method and an application thereof and belongs to the field of research of veterinary vaccines. Three recombinant proteins rApxIA, rApxIIA and rOMPD are expressed abundantly with a genetic engineering method and have better antigenicity. The rOMPD and rApxIA antibody levels of the mixed vaccine are higher than those during separate immunization of three proteins, the antibody level of rApxIIA and the antibody level of the mixed vaccine are remarkably higher than that of a control group, and the result proves that humoral immunity reaction induced by the recombined subunit mixed vaccine and rApxIA and rOMPD antibodies play an important role in cross immunization protection of mice. After inoculation, the genetic engineering subunit mixed vaccine is safe and harmless to an immune animal, is a novel vaccine with wide prospect, provides material reserve and technical support for control of porcine contagious pleuropneumonia in china and has great significance.

The invention discloses a method for preparing a bacterial ghost vaccine of haemophilus parasuis as well as a product and application thereof. The method comprises the following steps of connecting a mutational bacteriophage splitting gene E Eprom (as shown in SEQ ID No:1) with pBV220 to obtain an efficient splitting plasmid vector pBV-Eprom; converting the pBV-Eprom into haemophilus parasuis, propagating at 37 DEG C, and inducing the Eprom gene to express at 42 DEG C, and collecting the product which is unexpressed finally to obtain haemophilus parasuis bacterial ghost, wherein the Eprom is obtained by carrying out mutation on a promoter region of the bacteriophage splitting gene E, and the temperature for culturing bacteria is changed to 37 DEG C from the existing 28 DEG C by the Eprom; moreover, the splitting efficiency is high, the initial induced concentration and the large-scale production capacity are high, and the culture-splitting efficiency of a fermentation tank is as high as 99.99995%. The bacterial ghost vaccine of the haemophilus parasuis disclosed by the invention has good safety and immune protective efficacy, can be used for stimulating a body to generate a high-titration antibody, and also can be used for providing good cross immune protection for attack of a virulent strain of the haemophilus parasuis with different serotypes.

The invention discloses a porcine epidemic diarrhea virus antigen fusion protein, a coding gene and a porcine epidemic diarrhea vaccine prepared from the porcine epidemic diarrhea virus antigen fusion protein. The method comprises the following steps: screening to obtain a homosensory sequence of the spike protein of the porcine epidemic diarrhea virus, and fusing the homosensory sequence with a monomeric porcine ferritin heavy chain subunit to obtain an antigen fusion protein; in order to improve the expression quantity or the titer of the antigen fusion protein, the obtained antigen fusion protein is subjected to sequence optimization and then subjected to single-site or multi-site mutation, and the expression quantity and the titer of the obtained mutant are remarkably improved. According to the invention, a recombinant protein is expressed by using a silkworm or AcMNPV-insect cell and other eukaryotic expression systems to obtain a self-assembled ferritin nanoparticle antigen for displaying an S protein antigen protein on the surface of a cage structure of porcine ferritin, and a vaccine prepared from the prepared nanoparticle antigen can induce a widely neutralized anti-porcine epidemic diarrhea virus antibody; the porcine epidemic diarrhea virus vaccine has the potential of becoming a universal porcine epidemic diarrhea virus vaccine with cross immune efficacy.

The invention relates to a recombinant avian influenza virus strain. The recombinant avian influenza virus strain is obtained by recombination construction of an influenza virus strain and an avian influenza virus strain through a genetic recombination method, has no pathogenicity to chickens and chicken embryos, is safer than wild strains, and can effectively avoid divergence risk caused by incomplete inactivation. The invention also relates to a newcastle disease, infectious bronchitis and H9 subtype avian influenza resisting vaccine composition containing the recombinant avian influenza virus strain. The vaccine composition not only can prevent newcastle disease and infectious bronchitis, but also has good cross immunity to most H9N2 subtype avian influenza viruses currently prevalent in China. Therefore, compared with current commercial vaccines, the vaccine composition has wide cross protection in terms of H9N2 subtype avian influenza.

The invention discloses a streptococcus suis type 2 gene deletion strain as well as a construction method and application thereof, and belongs to the technical field of biological products. According to the invention, the B9H0105210 gene in the genome of the streptococcus suis serotype 2 SC19 is deleted in a homologous recombination manner for the first time, the hydrogen peroxide and nitric oxide stress resistance of the constructed streptococcus suis serotype 2 gene deleted strain is reduced, and the pathogenicity to mice is obviously weakened; moreover, the growth performance of the streptococcus suis type 2 gene-deleted strain is not greatly different from that of a wild strain SC19, the condition of gene recovery does not exist after continuous passage, and the streptococcus suis type 2 gene-deleted strain has an application prospect as an attenuated live vaccine, has a good immune protection effect on different genotypes of streptococcus suis such as the streptococcus suis type 2 strain SC19 and streptococcus suis type 2 P1 / 7, and has a good application prospect. And a certain cross immune protection performance is achieved.

The invention provides a novel three-antigen HSV-2 adjuvant subunit vaccine as well as a preparation method and application thereof. The vaccine comprises herpes simplex virus recombinant protein and a composite adjuvant, the herpes simplex virus recombinant protein comprises extracellular domains of three proteins, namely HSV-2gE, gD and gC, wherein the amino acid sequences of the extracellular domains of the HSV-2gE, the gD and the gC are respectively shown as SEQ ID NO.1, SEQ ID NO.2 and SEQ ID NO.3; and the composite adjuvant is composed of CpG oligodeoxynucleotide and QS-21. Experiments prove that by adding the composite adjuvant composed of CpG oligodeoxynucleotide and QS-21, the immunogenicity, in-vivo protectiveness, virus removal and other immune functions of the HSV-2 subunit vaccine can be remarkably improved; meanwhile, the vaccine is a cross immune protection vaccine of an HSV-2 virus strain and an HSV-1 virus strain.

The invention belongs to the field of biological medicines, and relates to a mutant protein vaccine aiming at tumor necrosis factor alpha (TNF-alpha) and applications of the mutant protein vaccine. The invention aims at providing the protein vaccine which is good in property and takes TNF-alpha as the target spot. According to the scheme, by immunizing the TNF-alpha mutant protein vaccine, the biological activity of the TNF-alpha mutant protein vaccine is inhibited, the cross immunologic reaction is generated in vivo, the biological functions of TNF-alpha are neutralized, and the autoimmune diseases and inflammatory diseases are inhibited. The protein vaccine aiming at TNF-alpha can be used for treating the autoimmune diseases and the inflammatory diseases and preventing the relapse of the autoimmune diseases and the inflammatory diseases.

The invention discloses a method for detecting AGEs (Advanced Glycation End Products) and application. The method comprises the following steps: firstly preparing a glassy carbon electrode modified bygraphene-chitosan / N(epsilon)carboxymethyl lysine, and then realizing multi-residue detection on five AGEs comprising the N(epsilon)carboxymethyl lysine, N(epsilon)carboxyethyl lysine, pentosidine, pyruvaldehyde imidazolinone and argpyrimidine by combining an indirect competition method on the basis of a principle that cross immunoreaction can be generated by a pentosidine monoclonal antibody andmultiple AGEs. According to the method for detecting the AGEs, disclosed by the invention, the problem that a current AGEs detecting method just can be used for detecting a single substance is solved,higher sensitivity (of which the detecting limit is 0.06 to 0.1 ng / mL) and wider linear range (0.1 to 1000 ng / mL) are obtained, the operation is simple, the cost is lower, the demands on clinical AGEs detection of a human body can be completely fitted, and important practical application value is obtained.

The invention discloses a broad-spectrum vibrio subunit vaccine for preventing fish pathogenic vibrio infection and a preparation method, belonging to the technical field of biology. The fusion protein OmpK-FlaA of an outer membrane protein OmpK with a conserved structure and a flagellin protein FlaA on the vibrio parahaemolyticus surface serves as an antigen component of the vaccine. The method is characterized by comprising the following steps of: superposing and extending Ppolymerase chain reaction (PCR) to the ompK and flaA genes of the vibrio parahaemolyticus to obtain a fusion protein gene flaA-ompK; constructing flaA-ompK-pET-28a recombinant plasmids; and obtaining the fusion FlaA-OmpK with high purity through exogenous induction expression and purification. The vaccine prepared bythe invention is safe and nontoxic and has no side effects; injection immune can be adopted; and the immune can also be realized by taking enteric microsphere vaccine orally; cross immunity protection can be acted to fish pathogenic vibrio (vibrio parahaemolyticus, vibrio alginolyticus, vibro harveyi, vibrio anguillarum and vibrio vulnificus).

The present invention provides a vaccine against a viral infection. The exemplary vaccine comprises a viral antigen of a vaccine strain of a virus; wherein the viral antigen is derived from a virus preparation of the vaccine strain of the virus; wherein the virus preparation of the vaccine strain of the virus contains a subpopulation of infectious viral particles, and the subpopulation of infectious viral particles is represented as a proportion over the total viral particles or total viral antigens of the virus preparation; and wherein the proportion of the subpopulation of infectious viral particles over the total viral particles or total viral antigens of the virus preparation is over a predefined threshold; so that the vaccine provides at least partial inter-subtypic or intra-subtypic cross immune response against different strains of the virus than the vaccine strain.

The invention provides a method for constructing a swine escherichia coli and haemophilus parasuis attenuated fusion strain. Strains with different immunogenicities are integrated into the same strain by a microorganism protoplast fusion technology. When a polyvalent vaccine is developed by pathogenic bacteria which have various serum types, but have no cross immune protection, the method is beneficial for improving unit antigen content of a single factor in the vaccine so as to fulfill the aim of improving the immune effect. Experimental research proves that compared with toxicity of a parent strain, toxicity of the novel fused strain is greatly reduced; and the fused strain reserves the antigen characteristics of the original parent strain. The method provides scientific basis and theoretical direction for developing a novel swine escherichia coli and haemophilus parasuis bigeminal attenuated vaccine.

Disclosed is a universal influenza vaccine composition and corresponding methods comprising at least one attenuated live-attenuated influenza vaccine. The vaccine composition can exhibit a cross-protective effect against a wide range of influenza viruses and can ensure a strong protection efficacy, a wide range of protection, and safety. In addition, a vaccination method of heterologous live vaccines of the present invention induces various immunological effects so that cross-immunogenicity and cross-protective ability are remarkably increased, and thus is expected to be usefully utilized as a universal influenza prevention method. A person who has a basal immunity through infection with an influenza virus or vaccination with an influenza vaccine can be regarded as being in a state where primary vaccination has already been performed, single vaccination with a live vaccine induces an enhanced cross-immune response, and thus it is possible to expect a wide range of protective effects against various viruses.

The invention discloses an influenza virus nano vaccine as well as a preparation method and application thereof. The invention relates to the field of biomedicine, and provides an influenza virus nano vaccine, which comprises nano particles and an STING agonist adsorbed on the surfaces of the nano particles, the nanoparticle comprises a polysaccharide antigen conjugate and a dendritic macromolecule, wherein the polysaccharide antigen conjugate is formed by coupling beta-glucan and influenza virus antigen protein, and the dendritic macromolecule and the polysaccharide antigen conjugate are adsorbed together. The immune response induced by the vaccine is higher than that of monomer immunogen protein without the adjuvant, body fluid, cell and mucosa immune response can be remarkably activated, lethal attack of an organism to H1N1 and H5N1 viruses can be effectively protected through nasal spray inoculation, and the nano vaccine can stimulate cross immune response and immune protection effect to different subtype influenza viruses.

The invention discloses a nanometer antigen particle based on self-assembled ferritin, an infectious bursal disease vaccine prepared from the nanometer antigen particle, and application. Infectious bursal disease virus VP2 structural protein is fused with a self-assembled ferritin nanometer subunit to obtain fusion protein. Parts of the sites of the infectious bursal disease virus VP2 structural protein are mutated, and therefore, the soluble expression quantity and the expression efficiency of a mutant are obviously improved. By use of a prokaryotic expression system and a bombyx mori and AcMNPV-insect cell eukaryotic expression system, recombined protein is expressed, or a recombinant baculovirus is subjected to gene submission in the body of a vertebrate to generate an antigen to induceto generate an antibody. The vaccine provided by the invention shows the infectious bursal disease virus VP2 structural protein on the surface of the cage structure of helicobacter pylori ferritin tocause a universal neutralization antibody capable of resisting the infectious bursal disease, immune potency is improved, an immune range is enlarged, and the vaccine provided by the invention has potential to become a universal vaccine with the cross immune potency.

The invention discloses an application of an electrochemical immunosensor in the aspect of multi-residue detection of sulfonamides. According to the application, firstly, the surface of a glassy carbon electrode is modified with polysulfadiazine with an in-situ electrochemical polymerization method, secondly, detection for four sulfonamides including sulfadiazine, sulfamethazine, sulfacetamide andsulfaguanidine is realized on the basis of cross-immune response of sulfadiazine antibodies and sulfonamides, wherein the limit of detection is in a range of 0.06-0.15 ng / mL, and linear range is 0.1-1500 ng / mL or 0.3-500 ng / mL.

The present invention discloses a 2.3.4.4b clade H5 subtype avian influenza virus strain and its application. The 2.3.4.4b clade H5 subtype avian influenza virus strain is avian influenza virus A / chicken / Shenyang / 12301 / 2024, which is deposited in the General Microbiological Center of the China Committee for Culture Collection of Microorganisms, with the deposit number of CGMCC No. 46299 and the deposit date of December 12, 2024. By searching for a 2.3.4.4b clade H5 subtype AIV with good cross-immune reaction as a vaccine candidate strain and preparing a whole virus inactivated vaccine, the present invention aims to effectively prevent and control the infection of recently prevalent H5 subtype AIV in poultry, and further eliminate the potential threat of influenza virus in poultry farming to public health safety.

The invention relates to preparation and application of a multi-epitope vaccine with cross immunity protective efficiency to O-type foot-and-mouth disease viruses such as OZK / 93, OR / 80MF8, OS / 99MF8, OHK93 and the like. The vaccine contains two sections of T cell auxiliary antigenic epitope polypeptides, 4-7 sections of antigenic epitope polypeptides related to main outer membrane proteins VP1, VP2 and VP3 of different foot-and-mount disease strains. The invention also relates to a preparation method of the vaccine and a clinical immunology application method. The vaccine has stable production preparation process and is applicable to mass production, experiments show that the multi-epitope vaccine is safe to use, infection of different O-type foot-and-mouth circulating strains can be effectively prevented and effective antibody titer can last for at least seven months.

The invention discloses an influenza vaccine and a preparation method based on self-assembled ferritin nanometer antigen particles. In the present invention, the extracellular domain of the influenza virus hemagglutinin protein is fused and expressed with the N-terminal of the self-assembled ferritin nanoparticle subunit, and the influenza virus hemagglutinin protein is displayed on the surface of the self-assembled ferritin cage structure. The invention carries out mutation optimization of the influenza virus hemagglutinin protein, improves its soluble expression amount and expression efficiency, improves the immune efficacy and breadth of the vaccine, and improves the immunogenicity of the influenza virus hemagglutinin protein. The present invention utilizes E. coli prokaryotic expression system, silkworm and AcMNPV-insect cell eukaryotic expression system to express and prepare recombinant protein vaccine respectively, or generate antigen and induce antibody production by gene presentation of recombinant baculovirus in vertebrate in vivo tissue. The influenza vaccine of the invention can induce broadly neutralizing anti-influenza antibodies, can not only improve the immune efficacy but also expand the immune range, and has the potential of a universal vaccine with cross-immunity efficacy.

The invention relates to biological immunity and a vaccine, and in particular discloses a coccidiosis vaccine component having a cross immunological protection capacity and a vaccine containing the coccidiosis vaccine component. The coccidiosis vaccine component is a transgenic coccidiosis strain capable of expressing heterogeneous coccidiosis immunity dominant antigens. The transgenic coccidiosis strain, which simultaneously has immunogenicities of a parental coccidiosis strain and a heterogeneous coccidiosis strain, can enhance the cross immunological protection capacity of the coccidiosis vaccine component when the transgenic coccidiosis strain serves as the coccidiosis vaccine component. Based upon experimental studies, it discovers that the cross immunological protection capacity, which is provided by the novel vaccine component, is positively correlated to the quantity of the expressed heterogeneous dominant antigens; therefore, preferably, a plurality of immunity dominant antigens are expressed. According to the coccidiosis vaccine component and a construction strategy thereof provided by the invention, the immunological protection capacity can be offered for various insect infections; and the cross immunological protection capacity is universal.

The invention discloses a rabies vaccine and application based on self-assembled ferritin nanometer antigen particles and prepared therefrom. In the invention, the rabies virus G antigen protein is fused with the self-assembled ferritin nanoparticle subunit to obtain a fusion protein. In the present invention, the rabies virus G antigen protein is subjected to site mutation, and the soluble expression amount and expression efficiency of the obtained mutant are significantly improved. The present invention utilizes prokaryotic expression system, silkworm and AcMNPV-insect cell eukaryotic expression system to express recombinant protein, or performs gene presentation in vertebrate body by recombinant baculovirus to produce antigen and induce antibody production. The rabies vaccine provided by the present invention displays antigenic proteins on the surface of the ferritin cage structure of Helicobacter pylori, causing broadly neutralizing anti-rabies virus antibodies, improving immune efficacy and expanding the scope of immunity, and has the potential of a universal vaccine with cross-immunity efficacy . The vaccine preparation method of the present invention is safe and convenient, and is suitable for rapid large-scale production.

The invention provides an actinobacillus pleuropneumoniae ghost vaccine, belonging to the field of microbiology and immunology. The actinobacillus pleuropneumoniae ghost vaccine contains actinobacillus pleuropneumoniae serotype 1 Shope ghost. The actinobacillus pleuropneumoniae ghost vaccine can completely prevent attack of the same serotype actinobacillus pleuropneumoniae, provide good cross immunity protection for other serotypes, and obviously reduce the cost of vaccines and epidemic prevention.

The invention discloses an antigen suitable for producing an anti-cryptochrome 4 antibody, which comprises an antigen core site Cry4-Ctem of pigeon cryptochrome 4 protein, the antigen core site Cry4-Ctem is located at 401-525 amino acids at the C terminal of the pigeon cryptochrome 4 protein, and the amino acid sequence of the antigen core site Cry4-Ctem is as shown in SEQ ID No.1. The antibody prepared from the antigen can specifically detect endogenous and exogenous expressed cryptochrome 4 protein by multiple methods (including Western Blot and immunofluorescence), and does not generate cross immune reaction with other proteins of corresponding species; in addition, the antigen used by the antibody is highly homologous with the multi-species cryptochrome 4, so that the multi-species cryptochrome 4 protein can be detected in a broad-spectrum manner.

The present invention provides GAS7 tumor antigen and its application. Specifically, the present invention provides an antigenic peptide of GAS7 protein, the antigenic peptide is composed of 7-25 amino acids, and the antigenic peptide is a T cell recognition epitope. The antigenic peptide of the present invention can effectively activate T cells that recognize natural tumor antigens, effectively increase their affinity, and induce stronger cross-immune reactions to natural peptides.